Fibrosis, enzymatic and non-enzymatic cross-links in Hypertensive heart disease

Michele M. Ciulla, Roberta Paliotti, Marina Carini, Fabio Magrini, Giancarlo Aldini

Research output: Contribution to journalArticle

Abstract

Myocardial fibrosis is commonly observed in left ventricular (LV) hypertrophied heart during Arterial Hypertension. This pathological change coupled with vascular stiffening with aging and diabetes may reduce the cardiovascular system elasticity contributing to the functional impairment. Both the LV adaptive response to the increasing blood pressure and the oxidative damage contribute to myocardial fibrosis; in particular, reactive oxygen species (ROS) induce the formation of reactive electrophilic carbonyl species by reacting with lipids and sugars which in turn react with proteins forming irreversible adducts (AGEs, ALEs and EAGLEs) and cross-links. The vascular wall matrix then becomes less distensible, as the formation of the adducts induces greater capacity in collagen to resist normal turnover. Therefore, monitoring cardiac fibrosis and markers of collagen synthesis, degradation and non-enzymatic cross-linking and the use of drugs that revert collagen accumulation and/or prevent/repair non-enzymatic cross-linking might represent a novel opportunity to alter the natural history of hypertensive heart disease. Recent evidences have suggested to target the excess of collagen cross-links; initial evidence seems to show that fibrosis is not affected to the same degree by all anti-hypertensive agents. ACEI and ARBs appear particularly effective. Finally, agents acting as cross-link breakers on AGEs or preventing AGEs formation or affecting the TTG activity are emerging.

Original languageEnglish
Pages (from-to)61-73
Number of pages13
JournalCardiovascular and Hematological Disorders - Drug Targets
Volume11
Issue number2
Publication statusPublished - Sep 2011

Fingerprint

Heart Diseases
Fibrosis
Collagen
Blood Vessels
Elasticity
Cardiovascular System
Antihypertensive Agents
Reactive Oxygen Species
Blood Pressure
Hypertension
Lipids
Pharmaceutical Preparations
Proteins

Keywords

  • Advanced glycation end products (AGEs)
  • Advanced lipoxidation end-products (ALEs)
  • Arterial hypertension
  • Either advanced glycation or lipoxidation endproducts (EAGLEs)
  • Left ventricular remodeling
  • Non-enzymatic cross-linking
  • Reactive oxygen species (ROS)
  • Regresison of myocardial fibrosis

ASJC Scopus subject areas

  • Molecular Medicine
  • Cardiology and Cardiovascular Medicine
  • Hematology
  • Pharmacology

Cite this

Ciulla, M. M., Paliotti, R., Carini, M., Magrini, F., & Aldini, G. (2011). Fibrosis, enzymatic and non-enzymatic cross-links in Hypertensive heart disease. Cardiovascular and Hematological Disorders - Drug Targets, 11(2), 61-73.

Fibrosis, enzymatic and non-enzymatic cross-links in Hypertensive heart disease. / Ciulla, Michele M.; Paliotti, Roberta; Carini, Marina; Magrini, Fabio; Aldini, Giancarlo.

In: Cardiovascular and Hematological Disorders - Drug Targets, Vol. 11, No. 2, 09.2011, p. 61-73.

Research output: Contribution to journalArticle

Ciulla, MM, Paliotti, R, Carini, M, Magrini, F & Aldini, G 2011, 'Fibrosis, enzymatic and non-enzymatic cross-links in Hypertensive heart disease', Cardiovascular and Hematological Disorders - Drug Targets, vol. 11, no. 2, pp. 61-73.
Ciulla, Michele M. ; Paliotti, Roberta ; Carini, Marina ; Magrini, Fabio ; Aldini, Giancarlo. / Fibrosis, enzymatic and non-enzymatic cross-links in Hypertensive heart disease. In: Cardiovascular and Hematological Disorders - Drug Targets. 2011 ; Vol. 11, No. 2. pp. 61-73.
@article{34e9510b460346b4a502a0969c236f62,
title = "Fibrosis, enzymatic and non-enzymatic cross-links in Hypertensive heart disease",
abstract = "Myocardial fibrosis is commonly observed in left ventricular (LV) hypertrophied heart during Arterial Hypertension. This pathological change coupled with vascular stiffening with aging and diabetes may reduce the cardiovascular system elasticity contributing to the functional impairment. Both the LV adaptive response to the increasing blood pressure and the oxidative damage contribute to myocardial fibrosis; in particular, reactive oxygen species (ROS) induce the formation of reactive electrophilic carbonyl species by reacting with lipids and sugars which in turn react with proteins forming irreversible adducts (AGEs, ALEs and EAGLEs) and cross-links. The vascular wall matrix then becomes less distensible, as the formation of the adducts induces greater capacity in collagen to resist normal turnover. Therefore, monitoring cardiac fibrosis and markers of collagen synthesis, degradation and non-enzymatic cross-linking and the use of drugs that revert collagen accumulation and/or prevent/repair non-enzymatic cross-linking might represent a novel opportunity to alter the natural history of hypertensive heart disease. Recent evidences have suggested to target the excess of collagen cross-links; initial evidence seems to show that fibrosis is not affected to the same degree by all anti-hypertensive agents. ACEI and ARBs appear particularly effective. Finally, agents acting as cross-link breakers on AGEs or preventing AGEs formation or affecting the TTG activity are emerging.",
keywords = "Advanced glycation end products (AGEs), Advanced lipoxidation end-products (ALEs), Arterial hypertension, Either advanced glycation or lipoxidation endproducts (EAGLEs), Left ventricular remodeling, Non-enzymatic cross-linking, Reactive oxygen species (ROS), Regresison of myocardial fibrosis",
author = "Ciulla, {Michele M.} and Roberta Paliotti and Marina Carini and Fabio Magrini and Giancarlo Aldini",
year = "2011",
month = "9",
language = "English",
volume = "11",
pages = "61--73",
journal = "Cardiovascular and Hematological Disorders - Drug Targets",
issn = "1871-529X",
publisher = "Bentham Science Publishers B.V.",
number = "2",

}

TY - JOUR

T1 - Fibrosis, enzymatic and non-enzymatic cross-links in Hypertensive heart disease

AU - Ciulla, Michele M.

AU - Paliotti, Roberta

AU - Carini, Marina

AU - Magrini, Fabio

AU - Aldini, Giancarlo

PY - 2011/9

Y1 - 2011/9

N2 - Myocardial fibrosis is commonly observed in left ventricular (LV) hypertrophied heart during Arterial Hypertension. This pathological change coupled with vascular stiffening with aging and diabetes may reduce the cardiovascular system elasticity contributing to the functional impairment. Both the LV adaptive response to the increasing blood pressure and the oxidative damage contribute to myocardial fibrosis; in particular, reactive oxygen species (ROS) induce the formation of reactive electrophilic carbonyl species by reacting with lipids and sugars which in turn react with proteins forming irreversible adducts (AGEs, ALEs and EAGLEs) and cross-links. The vascular wall matrix then becomes less distensible, as the formation of the adducts induces greater capacity in collagen to resist normal turnover. Therefore, monitoring cardiac fibrosis and markers of collagen synthesis, degradation and non-enzymatic cross-linking and the use of drugs that revert collagen accumulation and/or prevent/repair non-enzymatic cross-linking might represent a novel opportunity to alter the natural history of hypertensive heart disease. Recent evidences have suggested to target the excess of collagen cross-links; initial evidence seems to show that fibrosis is not affected to the same degree by all anti-hypertensive agents. ACEI and ARBs appear particularly effective. Finally, agents acting as cross-link breakers on AGEs or preventing AGEs formation or affecting the TTG activity are emerging.

AB - Myocardial fibrosis is commonly observed in left ventricular (LV) hypertrophied heart during Arterial Hypertension. This pathological change coupled with vascular stiffening with aging and diabetes may reduce the cardiovascular system elasticity contributing to the functional impairment. Both the LV adaptive response to the increasing blood pressure and the oxidative damage contribute to myocardial fibrosis; in particular, reactive oxygen species (ROS) induce the formation of reactive electrophilic carbonyl species by reacting with lipids and sugars which in turn react with proteins forming irreversible adducts (AGEs, ALEs and EAGLEs) and cross-links. The vascular wall matrix then becomes less distensible, as the formation of the adducts induces greater capacity in collagen to resist normal turnover. Therefore, monitoring cardiac fibrosis and markers of collagen synthesis, degradation and non-enzymatic cross-linking and the use of drugs that revert collagen accumulation and/or prevent/repair non-enzymatic cross-linking might represent a novel opportunity to alter the natural history of hypertensive heart disease. Recent evidences have suggested to target the excess of collagen cross-links; initial evidence seems to show that fibrosis is not affected to the same degree by all anti-hypertensive agents. ACEI and ARBs appear particularly effective. Finally, agents acting as cross-link breakers on AGEs or preventing AGEs formation or affecting the TTG activity are emerging.

KW - Advanced glycation end products (AGEs)

KW - Advanced lipoxidation end-products (ALEs)

KW - Arterial hypertension

KW - Either advanced glycation or lipoxidation endproducts (EAGLEs)

KW - Left ventricular remodeling

KW - Non-enzymatic cross-linking

KW - Reactive oxygen species (ROS)

KW - Regresison of myocardial fibrosis

UR - http://www.scopus.com/inward/record.url?scp=83455172393&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=83455172393&partnerID=8YFLogxK

M3 - Article

C2 - 22044034

AN - SCOPUS:83455172393

VL - 11

SP - 61

EP - 73

JO - Cardiovascular and Hematological Disorders - Drug Targets

JF - Cardiovascular and Hematological Disorders - Drug Targets

SN - 1871-529X

IS - 2

ER -